Drug resistance reversal—are we getting closer?
- 30 November 2003
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (17) , 2450-2461
- https://doi.org/10.1016/s0959-8049(03)00619-1
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Role of Intraperitoneal Chemotherapy in the Front-Line SettingJournal of Clinical Oncology, 2003
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsPublished by Elsevier ,2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.Journal of Clinical Oncology, 1996
- Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancerThe Lancet, 1992
- Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.Journal of Clinical Oncology, 1991
- Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.Journal of Clinical Oncology, 1990